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Hyaluronan (HA) is an extracellular matrix glycosaminoglycan
(GAG) involved in cell motility, proliferation, tissue remodeling,
development, differentiation, inflammation, tumor progression,
and invasion and controls vessel thickening in cardiovascular dis-
eases.Therefore, thecontrolofHAsynthesis couldpermit the fine-
tuning of cell behavior, but themechanisms that regulate HA syn-
thesis are largely unknown. Recent studies suggest that the
availability of the nucleotide-sugar precursors has a critical role.
Because the formation of UDP-sugars is a highly energetically
demandingprocess,wehave analyzedwhether the energy status of
the cell could control GAG production. AMP-activated protein
kinase (AMPK) is themainATP/AMP sensor ofmammalian cells,
and we mimicked an energy stress by treating human aortic
smooth muscle cells (AoSMCs) with the AMPK activators 5-
aminoimidazole-4-carboxamide-1--D-ribofuranoside and met-
formin. Under these conditions, HA synthesis, but not that of the
other GAGs, was greatly reduced. We confirmed the inhibitory
effect of AMPK using a specific inhibitor and knock-out cell lines.
We found that AMPK phosphorylated Thr-110 of human HAS2,
which inhibits its enzymatic activity. In contrast, the other two
HAS isoenzymes (HAS1 and HAS3) were not modified by the
kinase. The reduction of HA decreased the ability of AoSMCs to
proliferate, migrate, and recruit immune cells, thereby reducing
the pro-atherosclerotic AoSMC phenotype. Interestingly, such
effects were not recovered by treatment with exogenous HA, sug-
gesting that AMPK can block the pro-atherosclerotic signals
driven byHA by interaction with its receptors.
Hyaluronan (HA)3 is a ubiquitous and atypical glycosamino-
glycan (GAG) that is neither sulfated nor linked to any core
protein. It is composed of GlcUA and N-acetyl-D-glucosamine
GlcNAc and is synthesized by three plasmamembraneHA syn-
thases (HAS1, HAS2, and HAS3) that generate linear polymers
with molecular masses ranging from thousands to several mil-
lions of daltons (1). Many cellular effects of HA depend on its
viscoelastic properties, molecular mass, and membrane recep-
tors, including CD44, RHAMM (receptor for HA-mediated
motility), Lyve-1 (lymphatic vessel endothelial receptor 1),
HARE (HA receptor for endocytosis), and TLR4 (Toll-like
receptor 4), which trigger several signaling events (1). During
development, HA has a role in many critical events, including
cell migration and differentiation, through spatiotemporal reg-
ulation ofHAS expression in amphibians as well as inmammals
(2–5).
In cardiovascular pathologies, HA has critical pro-athero-
sclerotic properties (6). In normal arteries, HA is typically
located in the tunica adventitia, but following injuries, HA can
be found in themedia and neointima (7), where it canmodulate
the behavior of smooth muscle cells (SMCs) and contribute to
inflammatory responses, including recruitment of immune
cells (8, 9). SMCs have a critical role in vessel wall thickening
due to their proliferation, migration, and secretion of extracel-
lular matrix (ECM)-modifying enzymes (10). Moreover, SMCs
are responsible forHAmatrix deposition after vessel injury, and
HA itself canmodulate SMCmotility (11) and dedifferentiation
(12). Several experiments confirmed the critical pro-athero-
sclerotic role of HA using CD44 knock-out animals (12) or
HAS2 transgenic mice (13), by blocking HA/CD44 interaction
(14), or by inhibiting HA synthesis (15).
Therefore, regulation of HA synthesis could provide new
methods to treat vascular pathologies. Growth factors, cyto-
kines, prostaglandins, PKA, and PKC are known to modulate
HA synthesis through HAS activity and HAS gene expression,
although their physiological roles are not completely under-
stood (1). Our research and that of others have revealed the
critical role of the UDP-sugar precursors (UDP-GlcUA and
UDP-GlcNAc) in the regulation of HA synthesis (16, 17). The
ratio of NAD toNADH, which is influencedmainly by oxygen
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availability, is known to control UDP-GlcUA content through
the activity ofUDP-glucose dehydrogenase in cartilage and cor-
nea, which can lead to keratan sulfate synthesis (18).
The synthesis of HA precursors requires ATP, UTP, and
other critical metabolic molecules, including glucose, gluta-
mine, glucosamine, and acetyl-CoA (supplemental Fig. S1),
which makes GAG production an energy-consuming process.
As energy charge is critical for the regulation of all cellular
metabolism, we tested whether the ATP/AMP ratio could con-
trol the synthesis of HA and other GAGs. We focused our
attention on AMP-activated protein kinase (AMPK), which is
the main energy sensor of the eukaryotic cell (19). AMPK is a
heterotrimeric protein with a catalytic  subunit and two reg-
ulatory subunits ( and ) that, when the ATP/AMP ratio
decreases, inhibit anabolic processes and induce catabolic
pathways to restore ATP levels (20). The mechanism for acti-
vating AMPK is complex and involves phosphorylation of the
critical Thr-172 on the catalytic  subunit. By altering gene
expression or by directly phosphorylating several pivotal
enzymes, AMPK regulates cellularmetabolic processes, includ-
ing glycolysis, gluconeogenesis, lipid metabolism, and protein
synthesis. However, the consequences for the metabolism of
ECMcomponents are not yet known. Therefore, the aim of this
study was to determine how modulation of AMPK affects the
metabolism of HA and other GAGs in primary human aortic
SMCs (AoSMCs).
EXPERIMENTAL PROCEDURES
Cell Cultures and Treatments—Primary human AoSMCs
were purchased from Lonza and were grown for four to five
passages in complete SmGm2 culture medium (Lonza) supple-
mented with 5% FBS as described previously (15). 2.5  105
cells were seeded in 35-mm dishes, and after 6 h, SmGm2
mediumwas replaced with high glucose DMEM supplemented
with 0.2% FBS to induce quiescence. After 48 h, DMEM was
maintained in the positive control (quiescent cells), whereas it
was replaced with SmGm2 medium supplemented with 15%
FBS in the negative control (growth cells). In the treated cells,
DMEM was substituted with SmGm2 medium enriched with
15% FBS and supplemented with increasing concentrations
of 5-aminoimidazole-4-carboxamide-1--D-ribofuranoside
(AICAR), metformin, or 2-deoxyglucose (2-DG) (all from
Sigma).
Western Blotting—Western blot experiments were per-
formed as reported previously (14) using antibodies against
AMPK, phospho-AMPK (Thr-172), or phospho-acetyl-CoA
carboxylase (Ser-79) (all fromCell Signaling). To investigate the
phosphorylation of HAS2 at the putative AMPK target residue
Thr-110, we used a affinity-purified phospho-specific poly-
clonal antibody prepared in rabbit against the synthetic peptide
RKCLQSVKRLpTYPGIKV, which resembles residues 100–
116 of the human HAS2 sequence (Davids Biotechnologie,
Regensburg, Germany). As a control, we also used a polyclonal
antibodyagainst the samepeptidewithout threoninephosphor-
ylation (generated by the same company).
GAG Determinations—HA, chondroitin sulfate (CS), and
heparan sulfate (HS) released into the culture medium were
purified by proteinaseK (Finnzymes) and ethanol precipitation.
Streptomyces dysgalactiae hyaluronidase, chondroitinase ABC,
and heparinases I–III (all from Seikagaku) were used to obtain
the unsaturated () disaccharides, which were quantified by
HPLC analyses (21, 22). Pericellular HA matrices were visual-
ized using a particle exclusion assay (15).
Gene Expression Determinations by Quantitative RT-PCR—
Total RNAs were extracted from AoSMCs with TRIzol (Invitro-
gen), retrotranscribedusing theHighCapacity cDNAsynthesis kit
(AppliedBiosystems), and amplified on anABIPrism7000 instru-
ment (Applied Biosystems). The following human TaqMan gene
expression assays were used: HAS1 (Hs00155410_m1), HAS2
(Hs00193435_m1),HAS3 (Hs00193436_m1), UDP-glucose dehy-
drogenase (Hs00163365_m1), UDP-glucose pyrophosphorylase
(Hs00198879_m1), and -actin (Hs99999903_m1). The relative
gene expression was determined by comparingCt (14).
Cell Mobility and Adhesion Assays—Confluent AoSMCs
were growth-arrested by culture in DMEMwith 0.2% FBS for 2
days. The cells were scratched by blue tip and then cultured
under different conditions for 24 h. Migrated cells were quan-
tified as described previously (15). To assess the adhesiveness of
AoSMCs under different conditions, we performed monocyte
adhesion assays using the U937 monocyte cell line as reported
previously (15).
Cell Transfections—Primary AoSMCs were nucleofected
with 5 g of plasmid DNA using a Nucleofector apparatus
(Amaxa) and the human AoSMCNucleofector kit as described
previously (17) to have high efficiency and lowmortality.Wild-
type and knock-out mouse embryonic fibroblasts (MEF) and
COS-1 and COS-7 cells were efficiently transfected using
ExGen 500 (Fermentas) following the manufacturer’s protocol.
Microsome Purification and HAS Activity Assay—Control or
transfected COS-7 cells were lysed in 10 mM KCl, 1.5 mM
MgCl2, and 10 mM Tris-HCl (pH 7.4) supplemented with pro-
tease and phosphatase inhibitors (Roche Applied Science) by
scraping and sonication. The lysate was centrifuged at 5000 g
for 5 min at 4 °C, and the supernatant was centrifuged at
100,000 g for 40min at 4 °C to obtainmicrosomes containing
vesiculated fragments of the plasmamembrane (23). The pellet
was resuspended in the lysis buffer, and protein content was
determined byBradford assay. Twentyg of proteinswere used
to determine HAS activity as described previously (8).
Statistical Analyses—Statistical analyses of the data were
performed by analysis of variance, followed by Bonferroni post
hoc tests usingOrigin 7.5 software (OriginLab). Probability val-
ues of p 0.01 or 0.05 were considered statistically significant.
Experiments were repeated three times, each time in duplicate,
and data are expressed as means S.E.
RESULTS ANDDISCUSSION
Effects of AMPK Activation on GAG Synthesis—To induce
AMPKactivation,AoSMCswere incubated for 2 dayswith 0.2%
FBS to induce quiescence (positive control) and then treated for
48 h with 15% FBS (negative control) or with 15% FBS plus
AICAR, a pharmacological activator of AMPK that mimics
AMP, as previously reported inAoSMCs (24). ByWestern blot-
ting, we demonstrated that AICAR induced phosphorylation of
Thr-172 on the AMPK  subunit and that AICAR induced
AMPK activation by detecting phospho-acetyl-CoA carboxyl-
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ase, an AMPK target (Fig. 1A). In other experiments, quiescent
AoSMCs were treated for 48 h with metformin and 2-DG (Fig.
1A), which induce AMPK phosphorylation and activation
driven by different mechanisms from AICAR, i.e. through the
upstream kinase complex LKB1-STRAD-MO25 (25) and by
ATP depletion, respectively. These results showed that AICAR,
metformin, and 2-DG sustained phospho-AMPK and phos-
pho-acetyl-CoA carboxylase activities in 15% FBS in dose-de-
pendent responses.
At this time point, we collected aliquots of cell medium and
purified the secreted GAGs. Unsaturated () disaccharides
from HA, CS, and HS were obtained by digestion with specific
enzyme eliminases. The resulting -disaccharides were then
derivatized with 2-aminoacridone and quantified by HPLC
(21, 22). The treatment of quiescent AoSMCs with 15% FBS
induced an 2.5-fold increase in HA, whereas the addition of
15% FBS plus AICAR or metformin caused a dose-dependent
and statistically significant inhibition of HA synthesis (Fig. 1B).
In contrast, the synthesis of CS (both 6- and 4-sulfated isomers)
(Fig. 1B) as well as HS (supplemental Fig. S1) did not change
after the treatments, and onlyminor and not statistically signif-
icant modification of sulfation patterns were observed. These
results clearly demonstrate that HA synthesis, but not CS orHS
synthesis, is inhibited by both AICAR andmetformin. Previous
studies showed thatmetformin does not decrease sulfate incor-
poration into GAGs (26). However, because HA is not sulfated,
our results are novel and particularly interesting because of the
critical functions of HA in the vasculature. The “conventional”
GAG synthesis inhibitor 2-DG (27) was used as a control and
indeed reduced synthesis of both HA and CS (Fig. 1B). More-
over, HA, which remains associated with cell membranes to
form pericellular coats, also decreased after the treatments as
evaluated by particle exclusion assays (supplemental Fig. S2).
To confirm the results obtained with AICAR, AoSMCs were
also treated with dipyridamole, which inhibits AICAR trans-
port into cells by blocking an adenosine transporter, and with
5-amino-5-deoxyadenosine, which inhibits the cytosolic
phosphorylation of AICAR by blocking the adenosine kinase
(24). Both these treatments avoided the HA reduction induced
by AICAR (Fig. 1C).
To confirm the involvement of AMPK in HA synthesis inhi-
bition, we used Compound C, a specific AMPK inhibitor (25).
As shown in Fig. 2A, Compound C in the presence of AICAR
increased the HA level to near control levels. Therefore, these
data substantiate the critical involvement of AMPK in regulat-
ing HA synthesis. Furthermore, AoSMCs were nucleofected
FIGURE1.AICAR,metformin, and2-DG inhibitHAsynthesis butnotCS synthesis inAoSMCs.A,Westernblot analysis of 30gof protein extracts prepared
from quiescent AoSMCs (0.2% FBS, 48 h) or quiescent cells treated with 15% FBS or 15% FBS plus AICAR (1 and 2mM; 48 h), with 15% FBS plusmetformin (2, 3,
and 4 mM; 48 h), or with 15% FBS plus 2-DG (15, 25, 50, and 75 mM; 48 h; the high 2-DG concentrations were needed to compete with the 25 mM glucose
contained in the AoSMCs growth medium) using specific anti-phospho-AMPK (p-AMPK), anti-total AMPK (AMPK), or anti-phospho-acetyl-CoA carboxylase
(p-ACC) antibodies. In the 2-DG experiment, the 15% FBS sample also contained 50mM sorbitol as an osmotic control. The images are representative of three
independent experiments.B, quantificationof-HA,-C4S, and-C6Sprepared fromGAGs released into the culturemediumof quiescentAoSMCs treated for
48 h with 15% FBS, with 15% FBS plus AICAR (0.5, 1, 2, and 4 mM), with metformin (0.5, 1, 2, and 4 mM), or with 2-DG (12, 25, and 50 mM) as described for A.
C, relative quantification of-HA prepared fromGAGs released into the culturemedium of quiescent AoSMCs treatedwith 15% FBS, with AICAR (1 and 2mM),
with AICAR plus 10 M dipyridamole (Dipy), or with AICAR plus 10 M 5-amino-5-deoxyadenosine (AMDA). Results are expressed as means S.E. in three
different determinations. *, p 0.5; **, p 0.01, 15% FBS versus treatments, respectively.
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with a recombinant pcDNA3 plasmid coding for constitutively
activeAMPK(CA-AMPK)or fordominant-negativeAMPK(DN-
AMPK). The amount of HA secreted was dramatically decreased
after CA-AMPK nucleofection but did not change after
DN-AMPK nucleofection (Fig. 2B). Similarly, HA pericellular
coatswere abolishedbyCA-AMPKbutnotDN-AMPKtreatment
(supplemental Fig. S2). Interestingly, CS synthesis was not altered
by either of the treatments (Fig. 2B), indicating a specific role of
AMPK in HA synthesis.
To definitely demonstrate AMPK effects on HA synthesis,
we used MEFs from animals null in the 1 and 2 subunits of
AMPK (AMPK/) or from wild-type (AMPK/) mice, both
kindly provided by Benoît Viollet (28). In preliminary control
experiments, we verified the lack of AMPK activity in
AMPK/ MEFs by demonstrating the absence of the phos-
pho-acetyl-CoA carboxylase band in Western blotting as well
as the lack of cell cycle inhibition after AICAR addition (Fig. 2C
and supplemental Fig. S3). AMPK/ and AMPK/MEF cul-
tures were treated with 15% FBS or with 15% FBS plus AICAR
or metformin. After 48 h, AICAR and metformin reduced HA
released into the medium by60% in AMPK/MEF cultures
(Fig. 2D) and caused a near absence of cell-associated HA (sup-
plemental Fig. S4). As expected, CS was not affected by the
treatments (Fig. 2D). In contrast, HA in AMPK/ MEF cul-
tures was not changed by these treatments (Fig. 2D). These
results demonstrate that cells without AMPK activity are not
able to reduce HA synthesis in response to AICAR or met-
formin. The transfection of theCA-AMPK-coding plasmid into
AMPK/MEFs restored their ability to inhibit HA synthesis
(Fig. 2E). This clearly shows that the energy charge, through
AMPK activity, regulates HA synthesis and therefore affects
ECM composition.
FIGURE 2. AMPK is involved in AICAR- and metformin-dependent HA synthesis inhibition. A, relative HPLC quantification of -HA prepared from GAGs
released into the culture medium of quiescent AoSMCs treated with 15% FBS (set as 100%), with 15% FBS plus 1 mM AICAR, or with 15% FBS plus 1 mM AICAR
plus 100 M Compound C (Comp. C). B, relative HPLC quantification of -HA and -CS prepared from GAGs released into the culture medium of AoSMCs
nucleofected with an expression vector coding for CA-AMPK or DN-AMPK or with an empty vector (pcDNA3). The analyses were performed 48 h after the
nucleofections. The content of -HA, -C4S, or -C6S in control cells (i.e. subjected to the electrical protocol without DNA) was set to 100%. C, Western blot
analysis of 30g of protein extracts prepared fromquiescent (0.2% FBS, 48 h) wild-type (AMPK/) MEFs, fromAMPK/MEFs, or fromquiescent cells treated
with 15% FBS or with 15% FBS plus AICAR (1 and 2 mM; 48 h) using specific anti-phospho-AMPK (p-AMPK), anti-total AMPK, or anti-phospho-acetyl-CoA
carboxylase (p-ACC) antibodies. The absence of phospho-acetyl-CoA carboxylase bands in AMPK/MEFs indicates the absence of AMPK activity. D, relative
HPLCquantificationof-HAand-CSprepared fromGAGs released into the culturemediumofAMPK/MEFsorAMPK/MEFs incubated for 48hwith0.2%
FBS (quiescent), with 10% FBS (set as 100%), with 10% FBS plus 2mM AICAR, or with 10% FBS plus 4mMmetformin. *, p 0.5; **, p 0.01, 15% FBS (or control
in B or 10% FBS in C) versus treatments, respectively. E, relative HPLC quantification of -HA and -CS prepared from GAGs released into the culture medium
of AMPK/ MEFs, untransfected AMPK/ MEFs (control), or cells transfected with plasmid coding for CA-AMPK or DN-AMPK or with an empty vector
(pcDNA3).
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HA Does Not Influence AMPK-mediated Reduction of Cell
Proliferation, Migration, and Adhesiveness—SMCs are in-
volved in vascular diseases through their proliferation, intima
invasion, and recruitment of immune cells, and HA has a cen-
tral role to control SMC behavior. Therefore, we investigated
whether AICAR and metformin are able to modulate AoSMC
cell cycle responses. Using cytofluorometric analyses, we con-
firmed the previously published data (24) indicating that
AICARandmetformin, throughAMPK, can block the cell cycle
in G0/G1 phase without inducing cell death or apoptosis (data
not shown). Furthermore, the exogenous addition of high
molecular mass HA (average of4 106 Da; Healon) and the
exogenous addition of low molecular weight HA (prepared by
digesting Healon with testicular hyaluronidase for 90 min,
which generates oligosaccharides 500 kDa) to AICAR- or
metformin-treated cells maintained AoSMCs arrested in
G0/G1 (supplemental Fig. S5), suggesting that theHA-activated
signaling by specific cell-surface receptors cannot bypass the
block of the cell cycle induced by AMPK. These data confirm
the finding that highmolecular mass HA antagonizes mitogen-
induced S phase entry in vascular SMCs by modulating cyclin
D1 and p27kip1 (12, 29). On the other hand, by means of scratch
tests, we found that AMPK activity reduced cell migration by
70%, whereas AMPK inhibition by Compound C maintained
cell motility (Fig. 3A). The exogenous addition of high molecu-
larmassHAwas not able to bypass the blocking effect of AMPK
on cell migration (supplemental Fig. S5). This issue is interest-
ing, as high molecular mass HA is generally known to greatly
induce cellmobility, and by decreasingHA synthesis, AICARor
metformin could be useful to limit HA-dependent cell invasion
that is critical in several pathologies, such as cancer metastasis
or neointima formation. Interestingly, lowmolecular mass HA,
which is known to strongly induce cell motility, was able to
partially overcome the effects AICAR and metformin (supple-
mental Fig. S5). As in vivo HA can be fragmented during
neointima formation due to an inflammatory response (30), the
migration inhibitory effect of AMPK could be maintained also
in the presence of HA oligosaccharides that physiologically are
a strong activator of cell proliferation or motility.
AICAR and metformin treatments also strongly reduced
adhesion of fluorescent U937monocytes on AoSMCs, whereas
AMPK inhibition with Compound C maintained the number
of adherent monocytes comparable with the control (Fig. 3, B
and C). Interestingly, the monocyte binding in the Compound
C-treated samples confirmed the role of HA in cell adhesion
because enzymatic removal of HA and the exogenous high
molecular mass HA added to treated cells reduced monocyte
adhesion to near control levels. It is known that HA can mod-
ulate inflammation triggering TLR4 signaling (1) or can medi-
ate immune cell adhesion on the endothelium or SMCs via
CD44 (9, 31, 32). The results of these experiments demonstrate
that activation of AMPK in vitro inhibits proliferation, migra-
tion, and monocyte adhesion, thereby reducing AoSMC pro-
atherosclerotic behaviors.
Vessel thickening involves a plethora of causes partially still
unknown, but ECM remodeling is one of the main events
affecting vascular cells (33). Previous studies have shown that
administration of AICAR in vivo suppressed neointima forma-
FIGURE 3.AICAR andmetforminmodulate AoSMCmotility and adhesive
properties through AMPK. A, relative quantification of AoSMC mobility.
Quiescent confluent AoSMCs were treated with 15% FBS, with 15% FBS plus
AICAR (1mM), or with 15% FBS plusmetformin (2mM)with or without 100M
Compound C (Comp.C). After 24 h, cells were scratched using a pipette tip,
and after 24 h, migrated cells were counted. B and C, U937 monocyte adhe-
sion assays performed on AoSMCs treated with AICAR (B) or metformin (C).
Seventy percent quiescent confluent cells were treated with 15% FBS, with
15% FBS plus AICAR (1 mM), or with 15% FBS plus metformin (2 mM) with or
without 100 M Compound C. After 48 h, fluorescent U937 cells were added
for 20 min at 37 °C, washed, and counted under a fluorescence microscope.
Control experiments were done by treating AoSMCs with hyaluronidase
(Hyal) or by competing for cell-associated HA adding high molecular weight
HA (HMW-HA). Results are expressed as the number of adherent U937 cells
per field and are represented as means S.E. **, p 0.01, untreated versus
treated samples.
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tion after mechanical injury in the rat femoral artery, although
no information was provided on ECM composition (34). Fur-
thermore, it has been known for decades that metformin can
inhibit vascular complications of type 2 diabetes patients (35),
and AMPK has also been indicated as a therapeutic target for
atherosclerosis and cancer (36). Therefore, in addition to its
multiple effects on cell cycle progression and on protein, fatty
acid, and cholesterol synthesis (36), our results indicate that
AMPK can modulate ECM composition by inhibiting HA syn-
thesis, suggesting its pivotal role in all the processes that con-
tribute to matrix remodeling.
Molecular Mechanism of AMPK-mediated Inhibition of HA
Synthesis—To elucidate the critical effect of AMPK activation
only onHAsynthesis, we determinedwhetherAMPKcanmod-
ulate the expression of genes involved in HA metabolism. In
fact, it is known that AMPK controls the expression of several
genes, including the critical glucose metabolism transcription
factor FOXO (37). Therefore, by means of quantitative RT-
PCR, we quantified the relative content of mRNAs coding for
HA-metabolizing enzymes, including UDP-glucose pyrophos-
phorylase, UDP-glucose dehydrogenase, HASs, and hyaluroni-
dases after AoSMCs treatments with AICAR and metformin,
and we did not find any significant gene expression differences
(supplemental Fig. S6). The finding that UDP-glucose pyro-
phosphorylase and UDP-glucose dehydrogenase genes are not
modulated by AMPK could be reasonable considering that
UDP-glucose andUDP-GlcUA are critical not only for HA syn-
thesis but also for all other sulfated GAGs, glycogen, and other
glycoconjugates that are necessary for cell survival. However, a
proteomic study revealed that UDP-glucose pyrophosphory-
lase can be a target of AMPK in pigs, enhancing the complexity
of this issue (38).
Although HASs are known to be regulated at the transcrip-
tional level by several growth factors and cytokines (1), this
seems not to be the case for AMPK. As HASs are transmem-
brane proteins, their activity can be phospholipid-dependent
(39). Interestingly, AMPK can regulate mitochondrial cardioli-
pin content (40), and this lipid is known to regulate bacterial
HAS (39). As cardiolipin is typically in the mitochondria, this
issue could be not critical for eukaryotic HASs, although very
recently, it was reported that the AMPK 1 subunit can control
erythrocyte membrane elasticity (41). Therefore, AMPK could
modify membrane lipid composition indirectly by modulating
HAS activity or stability.
On the other hand, AMPK could act on HASs at a post-
translational level (i.e. phosphorylation), which would assure a
rapid response. Interestingly, the AMPK 1 subunit has a my-
ristoylation signal that localizes the AMPK complex in the
plasma membrane (42), where AMPK could interact with
HASs. Bioinformatic analyses have shown that HASs conserve
several AMPK consensus sequences in the intracytoplasmic
loop, which makes such enzymes hypothetical AMPK targets.
To study this issue, we transiently transfected COS-7 cells,
which are known to synthesize a limited amount of HA, with
plasmid coding for FLAG-tagged humanHAS1 (FLAG-HAS1),
HAS2 (FLAG-HAS2), or HAS3 (FLAG-HAS3) and measured
the HA released into the culture medium (Fig. 4A). Each con-
struct increased HA synthesis significantly. However, only the
FLAG-HAS2-transfected cells decreased HA synthesis to near
control levels when cotransfected with CA-AMPK but not with
DN-AMPK (Fig. 4A). This strongly suggests that only HAS2
can be targeted by AMPK. To evaluate whether AMPK can
modulate HAS functionality, we quantified the HAS enzymatic
activity in microsomes because HAS enzymes are transmem-
brane proteins, and their activity can be recovered only in crude
cell membranes. We found a strong reduction of HAS activity
only when FLAG-HAS2 was cotransfected with CA-AMPK,
whereas the functionality of other HAS enzymes (i.e.HAS1 and
HAS3) was not affected by CA-AMPK (Fig. 4B). Although
HASs share a high degree of amino acidic identity, the inhibi-
FIGURE 4. AMPK inhibits HAS2 activity. A, relative HPLC quantification of
-HA prepared fromGAGs released into the culturemedium 48 h after trans-
fection of COS-7 cells with the FLAG-HAS1-, FLAG-HAS2-, or FLAG-HAS3-ex-
pressing vector alone, cotransfection with the CA-AMPK- or DN-AMPK-ex-
pressing vector, or transfection with the empty pcDNA3 vector alone
(control). B, relative quantification of HAS enzymatic activity in microsomes
prepared from COS-7 cells transfected as described for A. C, relative quantifi-
cationofHASactivity inmicrosomeproteins extracted fromCOS-7 cells trans-
fected with FLAG-HAS2 or cotransfected with the FLAG-HAS2CA-AMPK- or
FLAG-HAS2DN-AMPK-expressing plasmid. In some experiments, mem-
brane fraction proteinswere preincubatedwith shrimp alkaline phosphatase
(SAP) to hydrolyze phosphate groups. Control experiments were done by
preincubating the sampleswith heat-inactivated SAP (boiled.SAP). Results are
represented asmeans S.E. *, p 0.05; **, p 0.01, untreated versus treated
samples.
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tory effect only onHAS2 activity seems to be very specific. From
a pathophysiological point of view,HAS2 transgenicmice exac-
erbate neointima formation after pro-atherosclerotic stimuli
(13); therefore, the specific inhibitory effect of AMPK on the
main HAS responsible of vessel thickening could be of crucial
pharmacological importance. Interestingly, the enzymatic
hydrolysis of protein phosphate groups in FLAG-HAS2CA-
AMPK microsomes, by treatment with shrimp alkaline phos-
phatase, restored HAS activity to the control level (Fig. 4C),
which strongly suggests that one ormore phosphorylation sites
in the HAS2 enzyme or in an accessory protein present in the
membrane can reduce HAS2 activity.
To identify critical phosphorylation residue(s), we searched
the Human Protein Reference Database, which revealed the
presence of a putative AMPKphosphorylation consensusmotif
in HAS2 protein at Thr-110. The sequence around this amino
acid is very well conserved in HAS2 proteins from zebrafish to
mouse (Fig. 5A), suggesting its importance. Moreover, this site
is not shared with HAS1 or HAS3, which would explain why
HAS1 andHAS3 are not regulated byAMPK. Furthermore, this
residue is on a cytoplasmic loop of HAS2 that was previously
shown to be important for glycosyltransferase activity (39).
Therefore, we mutated Thr-110 to alanine (T110A) in the
6-Myc-HAS2 plasmid to prevent phosphorylation and trans-
fected the mutant construct into COS-7 cells with or without
CA-AMPK. After 48 h, we measured the HAS-specific activity
in microsomes and found that the HA synthetic activity of the
T110A-transfected COS-7 cells was comparable with wild-type
HAS2 and that CA-AMPKwas not able to inhibit HA synthesis
(Fig. 5B). To determine whether Thr-110 could be phosphory-
lated, we used two polyclonal antibodies prepared against two
peptides that represent the HAS2 sequence from amino acids
100 to 116 in which Thr-110 was phosphorylated or not. As
shown in Fig. 5C, in Western blot experiments, the antibody
generated against the phosphopeptide (P-HAS2 panel) was able
to detect a band corresponding to HAS2 in protein extracts
prepared in COS-7 cells cotransfectedwith plasmids coding for
6-Myc-HAS2 and CA-AMPK. A faint band was also visible in
extracts prepared from transfection with only 6-Myc-HAS2,
where a small amount of HAS2 phosphorylation could be due
to endogenous COS-7 AMPK activity. The antibody generated
against the unphosphorylated peptide (HAS2 panel) was able to
detect HAS2 protein in both treatments, revealing similar
transfection efficiency. These results strongly suggest that Thr-
110 can be the target of AMPK and that the phosphorylation of
this amino acid drastically reduces the HA synthetic activity. A
previous study reported the phosphorylation of HAS3 without
describing the effect on enzyme functionality (43), whereas
another work clearly showed that ERK-mediated serine phos-
phorylation of all three HASs increased their specific activity
(44). This finding suggests that HAS proteins could have differ-
ent regulatory mechanisms in which the same post-transla-
tional modification (i.e. phosphorylation) in different sites
could increase or decrease the enzymatic activity. Moreover, a
recent work demonstrated that HAS2 and HAS3 can make
homo- and heterodimers and that HAS2 activity can be modu-
lated by ubiquitination at Lys-190 (45). Such results suggest
that HASs (and HAS2 in particular) can be complex proteins
with several possibilities for post-translational modifications
capable of modulating enzymatic activity.
Our findings demonstrate that at low ATP/AMP ratios,
AMPK activity can block HA synthesis without altering the
synthesis of other GAGs. The mechanism of such regulation
does not involve a change in gene expression but involves the
phosphorylation of HAS2, which decreases its HA synthetic
activity. When AMPK is active, cells are already known to be
growth-arrested, and for this reason, AMPK was indicated as a
therapeutic marker for cancer and vascular pathologies (36).
Our results highlight this point, demonstrating that AMPK can
deeply modify the ECM environment, thereby preventing cell
mobility and reducing pro-inflammatory cell recruitment,
which, in vivo, could be associated with reduced disease devel-
opment or progression. TheATP/AMP ratio depends on nutri-
ent availability, and glucose has a pivotal role in physiology. In
hypoglycemic conditions, cells have a low energy charge, and by
switching off non-vital anabolic processes (i.e. HA synthesis)
and concomitantly switching on lipid catabolism, AMPK can
thereby increase the ATP/AMP ratio and overcome stress peri-
ods. On the other hand, in hyperglycemic conditions, cells have
a high energy charge and inactiveAMPKbut can initiate several
intracellular stress responses that can lead to autophagy (46). In
this condition, HA synthesis is known to be dramatically ele-
vated, and HA cable-like structures can be produced extracel-
FIGURE 5. Identification of the critical residue involved in AMPK-depen-
dentHAS2 inhibition.A, alignment ofHAS2 sequences aroundThr-110 from
different organisms showing the conservation of the AMPK consensus site
(with critical residues shown in boldface). , hydrophobic residue; , basic
residue; x, any residue; §, serine or threonine. B, relative quantification of HAS
activity in microsome fractions prepared from COS-7 cells transfected with
the wild-type 6-Myc-HAS2 (HAS2)- or 6-Myc-HAS2 T110A (HAS2T100A)-ex-
pressingplasmidorwith theemptypcDNA3vector alone (control) or cotrans-
fected with the CA-AMPK-expressing vector. Results are expressed as
means S.E. **, p 0.01, pcDNA3 or HAS2CA-AMPK versus HAS2 samples.
C, Western blot analysis of 30 g of protein extracts prepared from untrans-
fected COS-7 cells (control) or fromCOS-7 cells transfectedwith plasmid cod-
ing for 6-Myc-HAS2 or an empty vector (pcDNA3) or cotransfected with plas-
mid coding for 6-Myc-HAS2 and CA-AMPK (HAS2CA-AMPK) using the
polyclonal antibody that recognizes phospho-Thr-110 (P-HAS2), tubulin (as a
loading control), or HAS2 (as a transfection efficiency control).
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lularly that are strongly adhesive for inflammatory cells (47). In
this context, a deeper knowledge of the mechanisms that con-
trol cellmicroenvironmentmetabolism (i.e. synthesis, degrada-
tion, and modifications) could identify critical factors involved
in pathologies, such as the role of AMPK in cardiovascular
diseases.
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